Merck & Co. Inc. may have decided against going ahead with commercialization plans for insulin glargine, but that doesn’t seem to have dampened Biocon Ltd.’s enthusiasm in the segment, at least for now.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?